GURU.Markets stock price, segment price, and overall market index valuation
The company's share price United Therapeutics
United Therapeutics' focus on treating rare diseases makes its stock sensitive to clinical trial results. Its price chart tells a story of success in developing unique drugs, patent protection, and addressing unmet medical needs.
Share prices of companies in the market segment - Specialized pharma
United Therapeutics is a biopharmaceutical company focused on treating rare lung diseases. We classify it as a Specialized Pharma company. The chart below reflects the overall performance of the biotech sector, where a company's value is determined by the success of its clinical trials.
Broad Market Index - GURU.Markets
United Therapeutics is a biotech company focused on developing drugs to treat rare diseases, particularly pulmonary arterial hypertension. Its market capitalization earns it a spot in the GURU.Markets index. The chart below shows the overall market performance. Compare this biotech player's stock to the overall trend.
Change in the price of a company, segment, and market as a whole per day
UTHR - Daily change in the company's share price United Therapeutics
For United Therapeutics, a company specializing in treating rare diseases, daily price changes reflect high volatility and reactions to biotech news. While the chart of these fluctuations is unspectacular, it is an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Specialized pharma
Specialty pharmaceuticals, where United Therapeutics operates, is a high-risk, high-reward sector. This chart shows the industry's average daily volatility. Comparing it to UTHR, a rare disease-focused company, allows us to assess how its niche position buffers it from general industry news.
Daily change in the price of a broad market stock, index - GURU.Markets
United Therapeutics is a biotech company specializing in the treatment of rare diseases, particularly pulmonary arterial hypertension. Biotech is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing UTHR stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization United Therapeutics
United Therapeutics is a biotechnology company specializing in the treatment of rare diseases. Its year-over-year performance reflects the commercial success of its drugs and investor confidence in its R&D platform, which is focused on new breakthrough drugs.
Annual dynamics of market capitalization of the market segment - Specialized pharma
United Therapeutics Corporation is a biotech company focused on treating rare diseases, particularly pulmonary arterial hypertension. Its niche expertise and strong pipeline of drugs provide it with a dominant position. The chart below shows how its unique specialization impacts its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
United Therapeutics is a biotechnology company specializing in the treatment of rare diseases, particularly pulmonary arterial hypertension. Its niche strategy and focus on orphan drugs ensures a strong market position and stable growth.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization United Therapeutics
United Therapeutics, a biotech company focused on rare diseases, displays monthly fluctuations in its price chart, reflecting sales data for its niche drugs, news about clinical trials of new drugs, and unique projects such as xenotransplantation.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
United Therapeutics is a biotech company specializing in developing drugs for rare diseases, particularly pulmonary arterial hypertension. Its sector dynamics, shown in the chart, reflect high risks. This allows us to assess how UTHR's dominant position in its niche and futuristic xenotransplantation projects influence its market valuation.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks, especially in the rare disease niche, can live their own lives, independent of the market. The chart below shows the overall sentiment. Does United Therapeutics follow the news about its drugs, or does its significant size and profitability force it to follow the market?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization United Therapeutics
Shares of United Therapeutics, which focuses on treating rare diseases, exhibit high weekly volatility. The price can fluctuate sharply in response to the publication of clinical trial data, regulatory decisions (such as the FDA), or news from competitors. For investors, this is an indicator of both scientific progress and market risks in a niche market.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
United Therapeutics' short-term performance reflects the volatility of the biotech sector as a whole. Investor risk sentiment, FDA news, and merger and acquisition trends affect everyone. The chart below provides a comparison of how the company's shares are performing against the backdrop of the overall volatility of the innovative pharmaceutical industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
United Therapeutics is a biotech company specializing in treating rare diseases. Its success depends on patents and clinical trial results, not on general economic cycles. This chart shows how its shares have a life of their own, often ignoring overall market volatility.
Market capitalization of the company, segment and market as a whole
UTHR - Market capitalization of the company United Therapeutics
United Therapeutics' market capitalization chart tells the story of its fight against rare diseases, expressed in financial terms. Its growth demonstrates investors' faith in the company's unique drugs, particularly those for the treatment of pulmonary hypertension. This metric's dynamics reflect both successful clinical trials and the commercial potential of its niche developments.
UTHR - Share of the company's market capitalization United Therapeutics within the market segment - Specialized pharma
United Therapeutics is a biotech company focused on treating rare diseases, particularly pulmonary hypertension. Its market capitalization in the specialty pharmaceuticals segment demonstrates its strong position in narrow but vital niches. The chart illustrates its standing among innovators.
Market capitalization of the market segment - Specialized pharma
The chart below shows the total market value of specialty pharmaceuticals, a sector in which United Therapeutics is a significant player. This market capitalization reflects both the risks of biotech development and the high hopes of investors for the development of breakthrough drugs. Market dynamics demonstrate the value of rare and life-saving drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Compared to the global market capitalization reflected in the chart, United Therapeutics stands out for its focus. The company creates value by developing drugs to treat rare diseases. Its market capitalization is a measure not of its mass appeal, but of its unique scientific expertise, offering hope where others fail.
Book value capitalization of the company, segment and market as a whole
UTHR - Book value capitalization of the company United Therapeutics
In the patent-ruled world of biotech, the United Therapeutics chart reveals the tangible side of innovation. It shows the growth of real assets: plants producing complex drugs and research centers. This is the physical foundation that enables scientific breakthroughs to be transformed into real, life-saving medicines.
UTHR - Share of the company's book capitalization United Therapeutics within the market segment - Specialized pharma
Despite its focus on biotechnology, United Therapeutics possesses significant tangible assets. Its market share is determined by its own R&D centers and unique manufacturing capabilities for developing drugs for rare diseases. This is the physical foundation of its scientific and commercial success.
Market segment balance sheet capitalization - Specialized pharma
United Therapeutics focuses on rare diseases, which requires significant investment in R&D and specialized laboratories. However, their business model is not as dependent on giant manufacturing plants as traditional pharma companies. A glance at the chart shows how the balance between intellectual and physical assets affects their book value.
Book value of all companies included in the broad market index - GURU.Markets
United Therapeutics' book value includes not only its offices but also cutting-edge laboratories and manufacturing facilities for developing rare drugs. The chart below clearly demonstrates how the company has built its scientific and industrial capabilities to save patients' lives.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - United Therapeutics
United Therapeutics' book value is its laboratories and factories. Its market value is the hope for its unique drugs for treating rare diseases. The chart below shows how many times investor faith in its scientific breakthrough exceeded the value of its tangible assets over different periods.
Market to book capitalization ratio in a market segment - Specialized pharma
United Therapeutics develops drugs for rare diseases, and its main assets are its patents. This chart shows a significant premium over book value, reflecting investors' confidence in the future revenue from unique drugs. Compare this premium with other biotech companies.
Market to book capitalization ratio for the market as a whole
United Therapeutics develops drugs for rare diseases, where value is created not by machines but by scientific breakthroughs. This metric averages market valuations, but for a biotech company like UTHR, market capitalization is a bet on the success of its patents and future monopoly revenues from unique drugs. The book value of its laboratories is almost irrelevant here.
Debts of the company, segment and market as a whole
UTHR - Company debts United Therapeutics
United Therapeutics operates at the forefront of biotechnology, developing treatments for rare diseases. The company's financial structure, shown in this chart, is a bet on the success of its scientific research. Raising capital allows it to finance multi-year clinical trials and bring life-saving, life-changing treatments to market.
Market segment debts - Specialized pharma
United Therapeutics focuses on rare diseases, which requires huge and risky investments in R&D. Debt can be used to finance breakthrough research or acquisitions. This chart shows how its financing tactics differ from other pharmaceutical companies with broader portfolios.
Market debt in general
United Therapeutics focuses on developing drugs for rare diseases, which requires colossal and risky investments in R&D. This chart, illustrating general credit market conditions, helps understand the cost of capital for such research-intensive companies. For UTHR, debt is fuel for years of clinical research that can save lives and generate enormous profits.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio United Therapeutics
United Therapeutics specializes in treating rare diseases, which requires huge and risky investments in R&D. This chart shows the company's debt to book value ratio. While leverage can accelerate the development of new drugs, failed clinical trials can turn this debt into a serious threat to the future.
Market segment debt to market segment book capitalization - Specialized pharma
United Therapeutics specializes in treating rare diseases, which requires colossal and risky investments in R&D. Debt policies in the biotech sector often reflect the clinical trial phase or the acquisition costs of promising developments. The chart illustrates the industry's collective bet on the future and UTHR's place in this strategy.
Debt to book value of all companies in the market
United Therapeutics develops drugs for rare diseases, which requires massive but uneven investments in R&D. The biotech's financial strategy differs significantly from that of industrial giants. This chart shows the average debt burden across the market, allowing one to assess the uniqueness and riskiness of UTHR's financing model on an economic scale.
P/E of the company, segment and market as a whole
P/E - United Therapeutics
United Therapeutics focuses on rare diseases, particularly pulmonary hypertension. This chart illustrates how much investors are willing to pay for the company's unique drug portfolio and its xenotransplantation developments. High values may indicate expectations for a breakthrough in research, while low values indicate concerns about patent protection.
P/E of the market segment - Specialized pharma
United Therapeutics is a biotech company focused on rare diseases, particularly pulmonary arterial hypertension. Their narrow focus requires significant investment in R&D. This chart serves as a barometer for the entire specialty pharmaceutical industry, showing whether investors are willing to pay a premium for innovation in niche segments.
P/E of the market as a whole
United Therapeutics develops drugs for rare diseases, and its history is being written in labs, not on the stock market. This chart shows investors' overall confidence in the economy, but UTHR's value is determined more by successful clinical trials and patents, creating a unique profile that often runs counter to the broader market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company United Therapeutics
United Therapeutics is a biotech company focused on treating rare diseases. This chart is a barometer of investor expectations for its research portfolio. Its fluctuations reflect news about clinical trials, potential breakthroughs in artificial organs, and patents that could dramatically change the company's future cash flows.
%20P%2FE%20United%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-United-Therapeutics&v=1772635800800 "Chart of the company's future (projected) P/E United Therapeutics")
Future (projected) P/E of the market segment - Specialized pharma
United Therapeutics is a biotech company focused on treating rare diseases, particularly pulmonary arterial hypertension. This chart shows the company's estimated future revenue in the context of the overall pharmaceutical sector. It demonstrates how much investors believe in UTHR's unique drug portfolio compared to the broader market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772635800803 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
United Therapeutics develops unique drugs for the treatment of rare diseases, particularly pulmonary hypertension. Compared to the overall market sentiment reflected by this indicator, UTHR's business stands out for its niche nature. Its success depends less on the overall economics and more on the results of clinical trials and patents, creating a unique risk-reward profile.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772635800804 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit United Therapeutics
United Therapeutics is a biotech company focused on treating rare diseases. Its business model is based on developing and selling unique, high-margin drugs for specific patient groups. This chart shows the net financial impact of this strategy, demonstrating the company's ability to profit from cutting-edge scientific research.
Profit of companies in the market segment - Specialized pharma
United Therapeutics specializes in treating rare diseases, which requires significant investment in research. The data in the chart illustrates the overall financial health of the biotech industry. For UTHR, this context determines the availability of capital for research and the market's willingness to pay premium prices for innovative, life-saving drugs.
Overall market profit
United Therapeutics develops unique drugs to treat rare and life-threatening diseases, such as pulmonary hypertension. Demand for its products is unaffected by economic ups and downs, making the business resilient to cycles. Therefore, by looking at this chart, an investor can assess how UTHR's path differs from the overall corporate revenue dynamics in the market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company United Therapeutics
United Therapeutics' profit forecasts are based on its dominance in the treatment of rare diseases, particularly pulmonary hypertension. Analysts are closely monitoring the patent protection of key drugs and the success of its R&D division, including breakthrough projects in the creation of artificial organs. The chart demonstrates the market's confidence in the sustainability of its unique business model.
%20profit%20of%20the%20company%20United%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-United-Therapeutics&v=1772635800953 "Graph of future (projected) profit of the company United Therapeutics")
Future (predicted) profit of companies in the market segment - Specialized pharma
United Therapeutics specializes in rare diseases, making its business less dependent on broad market cycles but more sensitive to research advances. The total revenue forecast for the specialty pharmaceuticals segment reflects the overall analyst sentiment, reflecting their belief in the commercial potential of new breakthrough drugs and future pricing strategies in the industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772635800967 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
United Therapeutics specializes in treating rare diseases, making its business relatively resilient to economic downturns. However, the overall corporate earnings trends presented here influence the investment climate in biotech. The chart provides context for assessing future funding opportunities for expensive innovative developments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772635800980 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - United Therapeutics
United Therapeutics specializes in drugs for rare diseases, which provides it with strong patent protection and high margins. This chart demonstrates how highly the market values its revenue. Every dollar of sales is considered extremely valuable due to the uniqueness of its products and the lack of direct competition, promising stable cash flows in the future.
P/S market segment - Specialized pharma
United Therapeutics specializes in treating rare and life-threatening diseases, such as pulmonary arterial hypertension. This chart shows the average revenue estimate in the pharmaceutical industry. It provides insight into how highly the market values the company's unique drug portfolio and its growth potential compared to other players generating similar sales.
P/S of the market as a whole
United Therapeutics is a biotech company focused on treating rare diseases, particularly pulmonary arterial hypertension. Its revenue depends on the success of its unique blockbuster drugs. The overall market backdrop shown in the chart allows one to compare the company's specific business model with the average revenue generation rate in the economy.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company United Therapeutics
United Therapeutics is a biotech company that fights rare lung and heart diseases and is even working on creating artificial organs. This chart visualizes the company's valuation in light of its expected future sales, reflecting investors' confidence in the success of its innovative drugs and transplant technologies.
%20P%2FS%20United%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-United-Therapeutics&v=1772635801081 "The graph of the company's future (projected) P/S United Therapeutics")
Future (projected) P/S of the market segment - Specialized pharma
United Therapeutics specializes in drugs for rare diseases, creating a unique market niche. The company's future revenue depends on the success of its concentrated portfolio of patented drugs. This chart allows you to assess how the market views the prospects of its highly specialized business model against the backdrop of pharmaceutical giants.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772635801091 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
United Therapeutics is a biotech company focused on rare diseases, particularly pulmonary hypertension. Developing and bringing such drugs to market requires significant investment. This chart shows the pulse of market optimism. High revenue expectations in the economy are driving capital inflows into biotech, which is vital for funding UTHR's research.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772635801161 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales United Therapeutics
United Therapeutics specializes in developing drugs for rare and life-threatening diseases, particularly pulmonary hypertension. This chart shows the commercial success of its highly specialized drug portfolio. Sales growth is directly dependent on the effectiveness of these drugs, their expanded use, and the company's ability to bring new innovative treatments to market.
Sales of companies in the market segment - Specialized pharma
United Therapeutics focuses on rare diseases, particularly pulmonary hypertension, developing life-saving treatments. The company is also a pioneer in the creation of artificial organs for transplantation. Its revenue breakdown clearly demonstrates which therapeutic areas and drugs are the company's primary growth drivers and financial stability.
Overall market sales
United Therapeutics specializes in developing drugs to treat rare diseases such as pulmonary arterial hypertension. The company's innovations and unique products not only save lives but also contribute to the high-margin biotech sector. This total revenue chart illustrates the overall economic picture, in which UTHR occupies a significant niche position.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company United Therapeutics
United Therapeutics specializes in the development and commercialization of unique drugs for the treatment of rare diseases, particularly pulmonary arterial hypertension. This graph reflects analysts' revenue expectations for the company, which are directly dependent on the successful launch of new drugs, the expansion of indications for existing ones, and patent protection.
%20sales%20of%20the%20company%20United%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-United-Therapeutics&v=1772635801351 "Schedule of future (projected) sales of the company United Therapeutics")
Future (projected) sales of companies in the market segment - Specialized pharma
United Therapeutics is a company focused on developing drugs for rare and life-threatening diseases, such as pulmonary hypertension. This chart shows the growth forecast for the entire specialty biopharmaceutical niche. It helps understand how quickly experts expect this complex yet vital market to grow, and its potential.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772635801373 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
United Therapeutics focuses on rare lung diseases and organ transplant production. The dynamics of this chart, which shows overall economic forecasts, are important to the company, as the availability of the expensive treatments and innovative therapies it offers depends on the stability of the healthcare system and the purchasing power of the population.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772635801388 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality United Therapeutics
This chart for United Therapeutics illustrates the financial results of a company focused on treating rare diseases. Its high margins are a result of the uniqueness and patent protection of its pulmonary arterial hypertension drugs. This allows it to charge high prices, while its narrow specialization optimizes marketing and research costs.
Market segment marginality - Specialized pharma
United Therapeutics is a biotech company focused on developing drugs for rare diseases. Their profitability is directly dependent on the exclusivity and efficacy of their patented drugs. This chart shows the financial results of their research activities. Outperforming the industry average indicates a strong market position and the high value of their portfolio.
Market marginality as a whole
United Therapeutics is a biotech company focused on treating rare diseases. Its success is determined by scientific breakthroughs and patents, not by the overall economic climate. This chart, which illustrates the cyclical nature of most businesses, only highlights the uniqueness of UTHR, whose fate is decided in laboratories and regulatory chambers.
Employees in the company, segment and market as a whole
Number of employees in the company United Therapeutics
United Therapeutics is a biotech company focused on rare diseases, particularly pulmonary hypertension. Its team, shown in this chart, consists primarily of scientists and clinicians. It's an army of intellect, fighting to extend and improve the lives of patients for whom standard treatments are ineffective.
Share of the company's employees United Therapeutics within the market segment - Specialized pharma
United Therapeutics specializes in treating rare diseases, which requires significant scientific resources. This metric reveals the company's unique structure: it's not an army of sales representatives, but a concentration of scientists, doctors, and researchers. The graph illustrates the share of the industry's intellectual capital the company devotes to fighting orphan diseases.
Number of employees in the market segment - Specialized pharma
United Therapeutics is a biotechnology company focused on treating rare and life-threatening diseases. It's at the cutting edge of science, where every employee is a valuable asset. The following headcount trend in this niche sector demonstrates the human resources required to develop breakthrough treatments and save patients' lives.
Number of employees in the market as a whole
United Therapeutics is at the forefront of biotechnology, developing unique treatments for rare diseases, particularly pulmonary hypertension. The overall employment dynamics in the market, shown in this chart, reflect the nation's economic health. Steady job growth indicates rising prosperity and increased spending on advanced medicine, creating a favorable environment for UTHR innovation.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company United Therapeutics (UTHR)
United Therapeutics is a biotechnology company specializing in drugs for rare diseases. This metric reflects the nature of its business: enormous market value is generated by a small team of scientists and specialists. Its high market value per employee is driven by the value of its patent portfolio and unique drugs, not the scale of its manufacturing capacity.
%20of%20the%20company%20United%20Therapeutics%20(UTHR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-United-Therapeutics-UTHR&v=1772635801736 "Chart of market capitalization per employee (in thousands of dollars) of the company United Therapeutics (UTHR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
United Therapeutics is a biotech company focused on treating rare diseases. In this industry, value is created not on the assembly line but in laboratories, and is protected by patents. This chart shows the industry's average market capitalization per employee. It demonstrates how UTHR's market value, based on its R&D, compares to that of its competitors on a per-scientist or per-employee basis.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772635801775 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
United Therapeutics specializes in rare diseases, developing unique drugs for pulmonary hypertension. This metric allows us to assess how the market rewards a research-intensive business. The high employee value here is a result of holding patents on life-saving drugs, which creates enormous value with a relatively small staff.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772635801798 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company United Therapeutics (UTHR)
United Therapeutics is a biotech company focused on rare (orphan) diseases. This chart illustrates the essence of their business model: colossal revenues from highly specialized, patented drugs are distributed among a relatively small staff of highly qualified scientists and specialists. Efficiency is achieved through product exclusivity, not through the scale of their workforce.
%20Chart%20United%20Therapeutics%20(UTHR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-United-Therapeutics-UTHR&v=1772635801829 "Company Profit Per Employee (in thousands of dollars) Chart United Therapeutics (UTHR)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
United Therapeutics is a biopharmaceutical company focused on treating rare diseases, particularly pulmonary hypertension. This chart shows the benchmark for "specialized pharma." In this sector, average profits per employee can be astronomical. It's a "blockbuster business," where a single patent for an orphan drug generates billions.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772635801853 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
United Therapeutics is a biotech company focused on treating rare diseases. This cross-section of average employee performance in the market highlights the unique nature of their niche. Innovative drug development is primarily a matter of intellectual capital, where a small team of scientists can create a product worth billions, which sets them apart from labor-intensive industries.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772635801895 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee United Therapeutics (UTHR)
United Therapeutics is a biotech company focused on rare diseases. This chart demonstrates how a small but highly skilled team can generate significant revenue through unique, patented drugs. Productivity here is measured not by quantity, but by the value of life-saving solutions created.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-United-Therapeutics-UTHR&v=1772635801942 "Sales chart per company employee United Therapeutics (UTHR)")
Sales per employee in the market segment - Specialized pharma
United Therapeutics specializes in rare diseases. Their model is not mass production, but rather deep scientific research and expensive, life-saving drugs. This chart allows us to evaluate their commercial viability. How effectively does their relatively small staff (including R&D) generate revenue compared to pharmaceutical giants? It's a question of balancing science and sales.
Sales per employee for the market as a whole
United Therapeutics is a biotech company focused on saving lives in rare diseases, particularly pulmonary hypertension. Their business isn't focused on mass-market pills, but rather highly specialized, complex, and very expensive drugs. This chart clearly demonstrates the colossal revenue their R&D team generates by developing these unique, high-margin drugs.
Short shares by company, segment and market as a whole
Shares shorted by company United Therapeutics (UTHR)
United Therapeutics (UTHR) is a biotech company focused on treating rare diseases, particularly pulmonary hypertension, and developing artificial organs. This chart shows bearish bets against the company. An increase in short positions often signals that investors are concerned about patent expirations on key drugs or failures in their innovative research.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-United-Therapeutics-UTHR&v=1772635802279 "Short Shares Chart for the Company United Therapeutics (UTHR)")
Shares shorted by market segment - Specialized pharma
United Therapeutics (UTHR) is a biotech company specializing in treating rare diseases, particularly pulmonary hypertension. Their focus is narrow but important. This chart reflects overall investor sentiment across the pharmaceutical industry. High readings here indicate that the market expects trouble for the entire biotech sector.
Shares shorted by the overall market
United Therapeutics (UTHR) is a company focused on treating rare, life-threatening diseases, particularly pulmonary hypertension. This chart shows the overall level of fear in the market. When investors panic, they seek safe havens. Demand for UTHR's life-saving drugs is unaffected by economic cycles. This makes the company a barometer: are investors seeking salvation in "non-cyclical" medicine?
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator United Therapeutics (UTHR)
United Therapeutics develops drugs to treat rare diseases, particularly pulmonary hypertension. A chart above 70 may reflect successful clinical trials or strong sales. Oversold levels (<30) are often associated with concerns about competition, R&D setbacks, or regulatory risks for its niche products.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-United-Therapeutics-UTHR&v=1772635802342 "RSI 14 indicator chart for the company's stock United Therapeutics (UTHR)")
RSI 14 Market Segment - Specialized pharma
United Therapeutics (UTHR) is a biotech company focused on rare diseases, particularly pulmonary hypertension. Their mission is to discover cures for previously untreatable conditions. This chart reflects the overall sentiment in the Specialty Pharma segment. It helps us understand whether UTHR is driven by its unique developments or whether the industry as a whole is experiencing speculative overheating or panic.
RSI 14 for the overall market
United Therapeutics (UTHR) is a biotech company focused on treating rare diseases, particularly pulmonary hypertension. It's a risky but potentially highly profitable sector. This chart measures overall market euphoria. At such times, investors may be more inclined to invest in biotechs. During a panic, they may avoid UTHR shares due to R&D risks.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast UTHR (United Therapeutics)
United Therapeutics (UTHR) specializes in treating rare diseases, particularly pulmonary hypertension. The company also invests in futuristic technologies, such as 3D organ printing. This chart shows how analysts assess the balance between the stable revenue from current drugs and the enormous, yet risky, potential of their research.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-UTHR-United-Therapeutics&v=1772635802434 "A chart showing analyst consensus forecasts for the expected stock price. UTHR (United Therapeutics)")
The difference between the consensus estimate and the actual stock price UTHR (United Therapeutics)
United Therapeutics is a biotech company focused on treating rare and life-threatening diseases, primarily pulmonary arterial hypertension. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the current stock price and the consensus target price, demonstrating whether experts believe in their niche drugs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-UTHR-United-Therapeutics&v=1772635802466 "A chart showing the difference between the consensus forecast and the actual stock price. UTHR (United Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
United Therapeutics is a biotech company specializing in rare diseases, primarily pulmonary hypertension. The company also researches xenotransplantation (porcine organ transplants). This chart shows analysts' overall expectations for the specialty pharmaceutical sector. It reflects whether experts believe niche drugs will be successful.
Analysts' consensus forecast for the overall market share price
United Therapeutics (UTHR) is a biotech company specializing in rare diseases, particularly pulmonary hypertension. Their focus is saving lives in niche but complex areas of medicine. This chart provides a consolidated expert view of the market as a whole. It helps assess the overall risk appetite in the economy, which is important for funding expensive biotech developments.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index United Therapeutics
United Therapeutics is a unique biopharmaceutical company focused on a rare disease: pulmonary arterial hypertension (PAH). They have built a dominant franchise in this niche. This chart is an integrated assessment of their dual strategy: a stable, profitable pipeline of PAH drugs balanced by their ambitious R&D programs in organ manufacturing and xenotransplantation.
AKIMA Market Segment Index - Specialized pharma
United Therapeutics is a life-saving biotech company, dominating the treatment of pulmonary hypertension (PAH) and pioneering xenotransplantation (pig organ transplantation). This summary metric evaluates R&D. The chart shows the segment average. This benchmark: how much do UTHR's niche dominance (PAH) and futuristic R&D (organs) differentiate it from the average pharma company?
The AKIM Index for the overall market
United Therapeutics is a biotech company focused on treating a rare and severe disease, pulmonary hypertension. The company also invests in xenotransplantation (porcine organs). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative scientific story, driven by the laws of biotech, compares to overall economic trends.
